Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

SYRS $15.15 0.6300 +4.34%
IDRA $1.95 0.0800 +4.28%
MRTX $5.30 0.2000 +3.92%
PPHM $0.36 0.0129 +3.75%
BPTH $1.12 0.0300 +2.75%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

INO $6.99 -1.3700 -16.39%
APRI $2.39 -0.2900 -10.82%
ARIA $9.37 -1.0100 -9.73%
MNKD $0.55 -0.0429 -7.22%
RDUS $47.54 -3.6000 -7.04%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next > | Last >>

The Delayed Gratification of Obamacare

(The Atlantic) Oct 17, 2016 - With the national rate of uninsured people at historic lows, why isn’t Obamacare more popular?
read article 

The VSED Exit: A Way to Speed Up Dying, Without Asking Permission

(New York Times) Oct 21, 2016 - Del Greenfield had endured repeated bouts of cancer over four decades, yet kept working as a peace activist in Portland, Ore., into her 80s. “She was a powerful force,” said her daughter, Bonnie Reagan.
read article 

Agony, Alarm and Anger for People Hurt by Theranos’s Botched Blood Tests

(Wall Street Journal) Oct 20, 2016 - Sheri Ackert worried she might have a new tumor. Steve Hammons stopped taking his blood-thinning medication. Kimberly Toy emptied the pasta and sweets from her cupboards and said: “I can’t believe this happened.”
read article (paid subscription required) 

Gilead Unveils Promising Hep C, Fatty Liver Data; Setbacks Elsewhere

(Reuters) Oct 20, 2016 - Gilead Sciences Inc on Thursday announced high cure rates across all types of hepatitis C in late stage studies testing a triple drug combination, and said another experimental drug showed promise in reducing liver scarring known as fibrosis in a midstage trial.
read article 

Federal Prosecutors Accuse Local Medical Practice of Fraud

(Poughkeepsie Journal [New York]) Oct 21, 2016 - A local medical group that treats patients with cancer and blood disorders took illegal kickbacks and filed false Medicare claims, according to a complaint filed by federal prosecutors.
read article 

Connecting the Moonshot to Patients

(ACCCBuzz) Oct 21, 2016 - The Cancer Moonshot framed Thursday’s sessions at the ACCC 33rd National Oncology Conference in St. Louis. “I’ve been privileged to be part of the conversations around the Moonshot,” ACCC President Jennie R. Crews, MD, MMM, FACP, told attendees in her opening remarks.
read article 

Myriad Genetics Inc. Forms Relationship with ION Solutions to Deliver Quality Hereditary Cancer Tests and Services to the Nation's Largest Network of Community Oncologists

(Myriad) Oct 21, 2016 - Myriad Genetics, Inc., a global leader in personalized medicine, and ION Solutions, a part of AmerisourceBergen, and the largest physician services organization specializing in the support of community oncology, announced today that they have entered into a relationship to deliver quality hereditary cancer test results and services to ION member practices.
read corporate press release 

Lawsuit Over Cellphones and Cancer Hits a Stumbling Block

(Wall Street Journal) Oct 20, 2016 - An appeals court in Washington, D.C., on Thursday dealt a setback to a long-running lawsuit against the wireless industry over health concerns surrounding cellphones, deciding that a different legal standard for evidence should have been applied.
read article (paid subscription required) 

WHO Essential Cancer Drug List: Out of Reach for Many

(Medscape Medical News) Oct 21, 2016 - Despite the rapidly rising global cancer burden, effective treatment continues to remain out of reach for many patients, according to a new study.
read article (free registration required) 

Defining the True Value of Innovation in Cancer Treatment

(BMS) Oct 20, 2016 - Bristol-Myers Squibb believes the current structure of the Institute for Clinical and Economic Review’s (ICER) value assessment model takes a static approach to what is an incredibly dynamic environment. In ICER’s most recent evidence report on treatments for non-small cell lung cancer (NSCLC), we found fundamental issues that we believe stem from its severely flawed methodology.
read corporate press release 

Study: First-of-its-Kind Online Chemotherapy Approval Protocol Accelerates Cancer Patients' Access To Proven Treatments

(Nasdaq) Oct 20, 2016 - A study of a new web-based tool piloted with select medical oncology practices in UnitedHealthcare's care provider network in Florida found 99 percent of cancer patients received approval for chemotherapy drug regimens immediately or within 24 hours. The pilot also reduced cancer drug costs by 20 percent compared to UnitedHealthcare's cancer drug costs nationally, and all treatments were evidence-based and in alignment with the recommendations of the nation's leading cancer centers.
read article 

Scientists Build a Better Cancer Drug to Pass Through Blood-Brain Barrier

(Hopkins Medicine) Oct 20, 2016 - In efforts to develop new treatments for brain cancer, scientists from Johns Hopkins Drug Discovery and the Kimmel Cancer Center's Bloomberg~Kimmel Institute for Cancer Immunotherapy report they have altered the structure of an experimental drug that seems to enhance its ability to slip through the mostly impermeable blood-brain barrier
read press release 

Could Diet Change Help Treat Blood Cancer or Transplant Patients?

(Scientific American) Oct 20, 2016 - A team of researchers from California and Japan has found that an essential amino acid plays a crucial role in the creation of blood stem cells—a discovery the scientists say could offer a potential alternative to chemotherapy and radiation in treating blood cancer patients.
read article 

Sexual Pain in Women After Cancer Is Common, and Too Often Ignored

(UC Davis CCC) Oct 20, 2016 - Painful sex in women after cancer treatment is relatively common, often treatable and needs to be addressed by medical providers, a UC Davis oncologist and researcher suggests.
read press release 

Roots of Resistance to Cancer Drugs Run Deeper Than a Single Gene

(Yale Cancer Center) Oct 20, 2016 - Searching for more individual genes to predict responses to breast cancer therapy may not work, a new study suggests. Instead, scientists and clinicians need to pay attention to abnormalities in networks of genes, Yale researchers report in a paper published Oct. 20 in the journal Annals of Oncology.
read article 

More American Men with Early-Stage Prostate Cancer Could Opt Out of Immediate Treatment

(NYU Langone Medical Center) Oct 20, 2016 - A new report on Swedish men with non-aggressive prostate cancer suggests that a lot more American men could safely choose to monitor their disease instead of seeking immediate radiation treatment or surgery.
read press release 

CEL-SCI Provides Update on Partial Clinical Hold on Phase 3 Clinical Trial

(Yahoo! Finance) Oct 21, 2016 - CEL-SCI Corporation announced today: following up on our press release issued on September 26, 2016, we have received the Partial Clinical Hold letter from the U.S. Food and Drug Administration (FDA). CEL-SCI has started working on a response to the FDA and will work diligently with the FDA to seek to have the partial clinical hold lifted.
read article 

FDA Approves Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Advanced Prostate Cancer

(StreetInsider) Oct 21, 2016 - Astellas Pharma Inc.and Pfizer Inc. today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to update the U.S. product labeling for XTANDI® (enzalutamide) capsules to include new clinical data versus bicalutamide from the TERRAIN study. The data demonstrate improvement in radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (CRPC) who were treated with enzalutamide compared to patients who were treated with bicalutamide.
read article 

Merck’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early

(Merck) Oct 21, 2016 - Merck, known as MSD outside the United States and Canada, today announced that the phase 3 KEYNOTE-045 trial investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS).
read corporate press release 

Amgen Announces Positive Top-Line Results From XGEVA® (Denosumab) Phase 3 Trial For Delay Of Bone Complications In Multiple Myeloma Patients

(TheStreet) Oct 20, 2016 - Study met primary endpoint of non-inferiority versus zoledronic acid in delaying bone complications known as skeletal-related events.
read article 

Sanders Seeks Ariad Data On Cancer Drug Price Hikes

(STAT/Pharmalot blog) Oct 20, 2016 - Call it Bernie Sanders vs. Ariad Pharmaceuticals, Act Two.
read article 

CDC: Sexually Transmitted Disease Rates Are Rising

(USA Today) Oct 20, 2016 - The most commonly reported sexually transmitted diseases reached an all-time high in 2015, according to the annual Sexually Transmitted Disease Surveillance Report released Wednesday by the Centers for Disease Control and Prevention.
read article 

FDA Panel Backs Allergan's Drug for Frequent Nightly Urination

(Reuters) Oct 19, 2016 - The benefits associated with Allergan Plc's experimental drug to treat frequent nightly urination outweigh the risks for certain patients, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.
read article 

Stop Insurers From Making End Runs Around Patients With Preexisting Conditions

(STAT) Oct 19, 2016 - For years, insurers dropped sick people from their plans or denied coverage due to preexisting conditions like cancer, keeping them from the care and medicines they needed.
read article 

Rigel's Bleeding Disorder Drug Fails Late-stage Study

(Reuters) Oct 20, 2016 - Rigel Pharmaceuticals Inc said its bleeding disorder drug failed in a late-stage study, sending its shares down 37 percent in premarket trading on Thursday.
read article